Latest News for UCBJF
I initiate UCB SA with a Buy rating, citing its successful pivot to high-growth immunology and neurology platforms. Bimzelx is the principal growth engine for UCBJY, with €2.23bn 2025 sales and multi-indication approvals driving robust operating leverage. Portfolio diversification via Fintepla, Rystiggo, and Zilbrysq offsets legacy erosion, while recent acquisitions add long-term optionality.
United Community Banks (UCB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.1 Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression2 and highlights the benefits of early diagnosis.3 ATLANTA, June 17, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in Brain…
United Community Banks, Inc. (UCB) M&A Call Transcript
VEEV's UCB pharmacovigilance deal expands Safety Suite adoption, supporting automation, compliance and long-term growth opportunities.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for UCBJF.
Senate Trading
No Senate trades found for UCBJF.
U.S. House Trading
No House trades found for UCBJF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.